APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Tumors (NETs) Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroendocrine Tumors (NETs) Treatment Market Outlook and Growth Opportunities 2026

Report ID 174016490422 December 2025193 pages

Choose your research edition.

Industry ResearchNeuroendocrine Tumors (NETs) Treatment Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Tumors (NETs) Treatment Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Tumors (NETs) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Tumors (NETs) Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Tumors (NETs) Treatment Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Neuroendocrine Tumors (NETs) Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroendocrine Tumors (NETs) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroendocrine Tumors (NETs) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroendocrine Tumors (NETs) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroendocrine Tumors (NETs) Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroendocrine Tumors (NETs) Treatment market include Novartis AG, Pfizer, Inc, Progenics Pharmaceuticals, IpsenPharma, Hutchison MediPharma Limited, Boehringer Ingelheim International, AVEO Oncology and Advanced Accelerator Applications, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroendocrine Tumors (NETs) Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroendocrine Tumors (NETs) Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroendocrine Tumors (NETs) Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroendocrine Tumors (NETs) Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroendocrine Tumors (NETs) Treatment Segment by Company

Novartis AG

Pfizer, Inc

Progenics Pharmaceuticals

IpsenPharma

Hutchison MediPharma Limited

Boehringer Ingelheim International

AVEO Oncology

Advanced Accelerator Applications

Neuroendocrine Tumors (NETs) Treatment Segment by Type

Somatostatin Analogs (SSAs)

Targeted Therapy

Other

Neuroendocrine Tumors (NETs) Treatment Segment by Application

Hospitals

Clinics

Other

Neuroendocrine Tumors (NETs) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuroendocrine Tumors (NETs) Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuroendocrine Tumors (NETs) Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroendocrine Tumors (NETs) Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroendocrine Tumors (NETs) Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumors (NETs) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumors (NETs) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumors (NETs) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroendocrine Tumors (NETs) Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroendocrine Tumors (NETs) Treatment industry.

Chapter 3: Detailed analysis of Neuroendocrine Tumors (NETs) Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuroendocrine Tumors (NETs) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuroendocrine Tumors (NETs) Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroendocrine Tumors (NETs) Treatment Industry Trends Table 2. Neuroendocrine Tumors (NETs) Treatment Industry Drivers Table 3. Neuroendocrine Tumors (NETs) Treatment Industry Opportunities and Challenges Table 4. Neuroendocrine Tumors (NETs) Treatment Industry Restraints Table 5. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroendocrine Tumors (NETs) Treatment Revenue Share by Company (2021-2026) Table 7. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Company (k units) & (2021-2026) Table 8. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Neuroendocrine Tumors (NETs) Treatment Average Price (US$/unit) of Company (2021-2026) Table 10. Global Neuroendocrine Tumors (NETs) Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuroendocrine Tumors (NETs) Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Neuroendocrine Tumors (NETs) Treatment Company, Product Type & Application Table 13. Global Neuroendocrine Tumors (NETs) Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroendocrine Tumors (NETs) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Somatostatin Analogs (SSAs) Table 18. Significant Companies of Targeted Therapy Table 19. Significant Companies of Other Table 20. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type (2021-2026) & (k units) Table 22. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type (2027-2032) & (k units) Table 23. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share by Type (2021-2026) Table 24. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share by Type (2027-2032) Table 25. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type (2021-2026) Table 29. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Clinics Table 32. Significant Companies of Other Table 33. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application (2021-2026) & (k units) Table 35. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application (2027-2032) & (k units) Table 36. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share by Application (2021-2026) Table 37. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share by Application (2027-2032) Table 38. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application (2021-2026) Table 42. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application (2027-2032) Table 43. Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2021-2026) & (k units) Table 45. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region (2021-2026) Table 46. Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2027-2032) & (k units) Table 47. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region (2027-2032) Table 48. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Region (2021-2026) Table 51. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Region (2027-2032) Table 53. Global Neuroendocrine Tumors (NETs) Treatment Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Neuroendocrine Tumors (NETs) Treatment Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Neuroendocrine Tumors (NETs) Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026) & (k units) Table 58. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2021-2026) Table 59. Global Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032) & (k units) Table 60. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2027-2032) Table 61. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Market Share by Country (2021-2026) Table 63. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Market Share by Country (2027-2032) Table 65. Novartis AG Company Information Table 66. Novartis AG Business Overview Table 67. Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 69. Novartis AG Recent Development Table 70. Pfizer, Inc Company Information Table 71. Pfizer, Inc Business Overview Table 72. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 74. Pfizer, Inc Recent Development Table 75. Progenics Pharmaceuticals Company Information Table 76. Progenics Pharmaceuticals Business Overview Table 77. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 79. Progenics Pharmaceuticals Recent Development Table 80. IpsenPharma Company Information Table 81. IpsenPharma Business Overview Table 82. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 84. IpsenPharma Recent Development Table 85. Hutchison MediPharma Limited Company Information Table 86. Hutchison MediPharma Limited Business Overview Table 87. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 89. Hutchison MediPharma Limited Recent Development Table 90. Boehringer Ingelheim International Company Information Table 91. Boehringer Ingelheim International Business Overview Table 92. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 94. Boehringer Ingelheim International Recent Development Table 95. AVEO Oncology Company Information Table 96. AVEO Oncology Business Overview Table 97. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 99. AVEO Oncology Recent Development Table 100. Advanced Accelerator Applications Company Information Table 101. Advanced Accelerator Applications Business Overview Table 102. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 104. Advanced Accelerator Applications Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Neuroendocrine Tumors (NETs) Treatment Distributors List Table 108. Neuroendocrine Tumors (NETs) Treatment Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Neuroendocrine Tumors (NETs) Treatment Product Image Figure 2. Global Neuroendocrine Tumors (NETs) Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuroendocrine Tumors (NETs) Treatment Sales (2021-2032) & (k units) Figure 5. Global Neuroendocrine Tumors (NETs) Treatment Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Neuroendocrine Tumors (NETs) Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Somatostatin Analogs (SSAs) Image Figure 10. Targeted Therapy Image Figure 11. Other Image Figure 12. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share by Type (2021-2032) Figure 15. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Other Image Figure 21. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share by Application (2021-2032) Figure 24. Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application (2021-2032) Figure 27. Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. North America Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032) & (US$ Million) Figure 38. South America Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Neuroendocrine Tumors (NETs) Treatment Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Neuroendocrine Tumors (NETs) Treatment Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Somatostatin Analogs (SSAs)
  • Targeted Therapy
  • Other
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Novartis AG
  • Pfizer, Inc
  • Progenics Pharmaceuticals
  • IpsenPharma
  • Hutchison MediPharma Limited
  • Boehringer Ingelheim International
  • AVEO Oncology
  • Advanced Accelerator Applications

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuroendocrine Tumors (NETs) Treatment Market Dynamics
  1. 2.1 Neuroendocrine Tumors (NETs) Treatment Industry Trends
  2. 2.2 Neuroendocrine Tumors (NETs) Treatment Industry Drivers
  3. 2.3 Neuroendocrine Tumors (NETs) Treatment Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Tumors (NETs) Treatment Industry Restraints
3 Neuroendocrine Tumors (NETs) Treatment Market by Company
  1. 3.1 Global Neuroendocrine Tumors (NETs) Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Neuroendocrine Tumors (NETs) Treatment Company Ranking (2024-2026)
  6. 3.6 Global Neuroendocrine Tumors (NETs) Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuroendocrine Tumors (NETs) Treatment Company Product Type and Application
  8. 3.8 Global Neuroendocrine Tumors (NETs) Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuroendocrine Tumors (NETs) Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuroendocrine Tumors (NETs) Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuroendocrine Tumors (NETs) Treatment Market by Type
  1. 4.1 Neuroendocrine Tumors (NETs) Treatment Type Introduction
  2. 4.1.1 Somatostatin Analogs (SSAs)
  3. 4.1.2 Targeted Therapy
  4. 4.1.3 Other
  5. 4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type
  6. 4.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type
  10. 4.3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (2021-2032)
  12. 4.3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type (2021-2032)
5 Neuroendocrine Tumors (NETs) Treatment Market by Application
  1. 5.1 Neuroendocrine Tumors (NETs) Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application
  6. 5.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application
  10. 5.3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application (2021-2032)
6 Neuroendocrine Tumors (NETs) Treatment Regional Sales and Value Analysis
  1. 6.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2027-2032)
  5. 6.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Neuroendocrine Tumors (NETs) Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Country, 2025 VS 2032
7 Neuroendocrine Tumors (NETs) Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032)
  6. 7.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuroendocrine Tumors (NETs) Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Pfizer, Inc
  8. 8.2.1 Pfizer, Inc Company Information
  9. 8.2.2 Pfizer, Inc Business Overview
  10. 8.2.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  12. 8.2.5 Pfizer, Inc Recent Developments
  13. 8.3 Progenics Pharmaceuticals
  14. 8.3.1 Progenics Pharmaceuticals Company Information
  15. 8.3.2 Progenics Pharmaceuticals Business Overview
  16. 8.3.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  18. 8.3.5 Progenics Pharmaceuticals Recent Developments
  19. 8.4 IpsenPharma
  20. 8.4.1 IpsenPharma Company Information
  21. 8.4.2 IpsenPharma Business Overview
  22. 8.4.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  24. 8.4.5 IpsenPharma Recent Developments
  25. 8.5 Hutchison MediPharma Limited
  26. 8.5.1 Hutchison MediPharma Limited Company Information
  27. 8.5.2 Hutchison MediPharma Limited Business Overview
  28. 8.5.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  30. 8.5.5 Hutchison MediPharma Limited Recent Developments
  31. 8.6 Boehringer Ingelheim International
  32. 8.6.1 Boehringer Ingelheim International Company Information
  33. 8.6.2 Boehringer Ingelheim International Business Overview
  34. 8.6.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  36. 8.6.5 Boehringer Ingelheim International Recent Developments
  37. 8.7 AVEO Oncology
  38. 8.7.1 AVEO Oncology Company Information
  39. 8.7.2 AVEO Oncology Business Overview
  40. 8.7.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  42. 8.7.5 AVEO Oncology Recent Developments
  43. 8.8 Advanced Accelerator Applications
  44. 8.8.1 Advanced Accelerator Applications Company Information
  45. 8.8.2 Advanced Accelerator Applications Business Overview
  46. 8.8.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  48. 8.8.5 Advanced Accelerator Applications Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroendocrine Tumors (NETs) Treatment Value Chain Analysis
  2. 9.1.1 Neuroendocrine Tumors (NETs) Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroendocrine Tumors (NETs) Treatment Sales Mode & Process
  6. 9.2 Neuroendocrine Tumors (NETs) Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroendocrine Tumors (NETs) Treatment Distributors
  9. 9.2.3 Neuroendocrine Tumors (NETs) Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst